Dasatinib is a second-generation BCR-ABL inhibitor with a higher inhibitory efficacy toward the kinase activity of the BCR-ABL oncogene [26] and is widely used to treat CML patients. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.